EUVIMEDEUVIMED entdecken
Crossref

Exploratory evaluation of CA 15-3 × NLR score for predicting pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy

Emine Bihter Eniseler, Bartu Çetin, Ferhat Ekinci, Atike Pınar Erdoğan, Mustafa Şahbazlar

Clinical and Translational Oncology · 2025

DOI: 10.1007/s12094-025-04031-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2025. Verfasst von Emine Bihter Eniseler und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey. drbihtereniseler@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Neutrophils, Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aimed to evaluate the predictive role of the CA 15-3 × neutrophil-to-lymphocyte ratio (NLR) score in estimating pathologic complete response (pCR) in patients with invasive breast cancer who underwent neoadjuvant chemotherapy (NACT). METHODS: A total of 330 patients treated with NACT between January 2015 and March 2025 were retrospectively analyzed. The CA 15-3 × neutrophil-to-lymphocyte ratio (NLR) score was calculated by multiplying pre-treatment serum CA 15-3 levels with the NLR. pCR was defined as the absence of invasive carcinoma in both the breast and axillary lymph nodes after surgery. Logistic regression analyses were performed to identify independent predictors of pCR, and receiver operating characteristic (ROC) curve analysis was conducted to determine the optimal cutoff value for the composite score. RESULTS: The median age of the study population was 48 years. Pathologic complete response was achieved in 42.4% of patients. The median CA 15-3 × NLR score was significantly lower in the pCR group compared to the non-pCR group (21 vs. 24; p = 0.033). ROC analysis revealed an optimal cutoff value of ≤ 32.7 (AUC = 0.568), with 81.05% sensitivity and 33.9% specificity. In multivariate logistic regression analysis, CA 15-3 × NLR ≤ 32.7 remained an independent predictor of pCR (OR 1.931; 95% CI 1.086-3.433; p = 0.025), along with N stage 2 and the absence of perineural invasion. CONCLUSION: The CA 15-3 × NLR score demonstrates modest prognostic potential in predicting treatment response in breast cancer patients receiving neoadjuvant chemotherapy. While promising, these findings should be interpreted cautiously, and further validation is needed before clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyNeutrophilsLymphocytesHumansFemaleMiddle AgedRetrospective StudiesAdultAgedChemotherapy, AdjuvantROC CurvePrognosisPathologic Complete Response

Stichwörter der Autor:innen

Breast cancerCA 15-3NLRpCR

Autor:innen und Institutionen

  • Department of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey. drbihtereniseler@gmail.com.
  • Department of General Surgery, Manisa City Hospital, Manisa, Turkey.
  • Department of Medical Oncology, Manisa Celal Bayar University, Manisa, Turkey.

Zitieren

APA

Eniseler, E. B., Çetin, B., Ekinci, F., Erdoğan, A. P., & Şahbazlar, M. (2025). Exploratory evaluation of CA 15-3 × NLR score for predicting pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-025-04031-8

Vancouver

Eniseler EB, Çetin B, Ekinci F, Erdoğan AP, Şahbazlar M. Exploratory evaluation of CA 15-3 × NLR score for predicting pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Clinical and Translational Oncology. 2025. doi:10.1007/s12094-025-04031-8

BibTeX
@article{Eniseler2025,
  author = {Eniseler, Emine Bihter and Çetin, Bartu and Ekinci, Ferhat and Erdoğan, Atike Pınar and Şahbazlar, Mustafa},
  title = {Exploratory evaluation of CA 15-3 × NLR score for predicting pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy},
  journal = {Clinical and Translational Oncology},
  year = {2025},
  doi = {10.1007/s12094-025-04031-8}
}
Kostenlos starten →